187
The big US pharmaceutical Merck has formalized the acquisition of Acceleron Pharma. Following the anticipations of the Wall Street Journal in recent days, the two companies announced today that they have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for 180 dollars per share in cash for an approximate total value of 11.5 billions of dollars. The transaction is expected to close in the fourth quarter of 2021.